SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT IN RELATION TO MIXED PROTAMINE HUMAN INSULIN INJECTION (30R) — PREFILLED PEN-TYPE OBTAINED MARKETING APPROVAL FROM CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the Mixed Protamine Human Insulin Injection (30R) — Prefilled Pen-type (the "**Product**"), which is independently researched and developed by the Group, has obtained marketing approval from China National Medical Products Administration ("**NMPA**"). Such approval further enriches the Company's drug product line in the field of diabetes and provides diabetic patients in China with a wide range of more convenient insulin treatment.

The Product adopts a classic premixed ratio of 30% soluble human insulin (short-acting) and 70% protamine human insulin (intermediate-acting), which precisely matches clinical needs in dosage form design and specification configuration, eliminating the need for frequent combination therapy, effectively simplifying treatment plan, helping patients achieve more stable blood glucose control and improving their quality of life.

(1) Optimizing Insulin Concentration and Dose Scale for Precise Glucose Management

It can be tailored to individual patient's body weight and blood glucose fluctuation patterns, which minimizes the inconvenience of high-volume injections and reduces dosing errors during small adjustments, significantly enhancing dosing accuracy.

(2) Prefilled Pen-type with Ready-to-use Simple Three-step Operation to Improve Compliance

It eliminates the need to replace cartridges or maintain the pen, streamlining the injection process, and reducing risks of mechanical wear, dosing deviation and contamination caused by improper installation or repeated use. It also eliminates cumbersome steps such as priming or adjustment, lowering operational difficulty for patients with visual impairment, reduced dexterity, or of older age, thereby improving medication compliance.

(3) Compact and Portable to Suit Various Daily Scenarios, Enhancing Quality of Life

The prefilled pen-type is portable for on-the-go injections without requiring additional consumables such as syringes. It adapts to workplace, travel and other daily scenarios, overcoming the limitations of traditional injections. This enhances convenience and confidence in diabetes management, improving the overall treatment experience and supporting long-term prognosis of patients.

As of today, diabetes has become the third most serious noncommunicable disease threatening human health worldwide, following cancer, cardiovascular and cerebrovascular diseases, and standardised long-term treatment is crucial for prognosis of patients. The Group, which has long been involved in the treatment of diabetes with a comprehensive portfolio of insulin and biosimilar products, is one of the few companies in the world with the capability to research, develop and commercialise a full range of insulin products. The Group has independently researched and developed five insulin products, namely, Recombinant Human Insulin Injection, Insulin Glargine Injection, Insulin Aspart Injection, Insulin Aspart 30 Injection and Mixed Protamine Human Insulin Injection (30R), all of which have been approved for marketing. The Furthermore, all 5 products won the bid for National drugs centralized bulk procurement, effectively reducing the medication burden of patients and improving drug accessibility.

Leveraging its comprehensive competitive advantages in insulin R&D and manufacturing, the Group's Insulin Glargine is currently placed under the United States (U.S.) Biologics License Application (BLA) stage, such that the Company could become the first corporation whose Insulin Glargine to obtain marketing approval in the U.S. market under a Phase III clinical trial waiver, and may also become the first Chinese company whose insulin product to be marketed in the U.S., thereby supporting the promotion of high-quality domestic insulin products in global market.

Against the backdrop of China's national centralized procurement policy, the Group's insulin portfolio, distinguished by its ''safe, convenient, and cost-effective'' core values, has become the trusted choice for an increasing number of diabetes patients. The approval of the Mixed Protamine Human Insulin Injection (30R) — Prefilled Pen-type represents an important enhancement to the Group's diabetes treatment portfolio.

Going forward, the Group will continue to pursue a strategy focused on maximizing benefits under national centralized procurement, internationalizing in emerging markets, and differentiating product portfolios. It will concentrate on research and development of ultra-long-acting insulins and combination formulations, continuously improving patient adherence, supporting more stable blood glucose control and multiple metabolic benefits, thereby providing more effective and accessible treatment options for diabetes patients in China and worldwide.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
16 April 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.